As part of The Wistar Institute's Melanoma Research Center, the Villanueva lab pursues new ways to overcome the challenge of melanoma drug resistance. In this paper, the group took aim at melanomas ...

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant ...

MAPK pathway: uncontrolled growth via the MAPK pathway promotes melanoma cell growth.The pathway provides several sites for potential pharmacologic inhibition.RTK: Receptor tyrosine kinase.

[31] Activation of this pathway results in the phosphorylation of MAPK, which then phosphorylates other factors and kinases, ultimately regulating cell survival, proliferation, and differentiation.

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. .

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

A Deep Cyclic Inhibitor (DCI) of the mitogen-activated protein kinase (MAPK) pathway, IMM-6-415 ... durability in animal models of RAF mutant melanoma and colorectal cancer.

As part of The Wistar Institute’s Melanoma Research Center, the Villanueva lab pursues new ways to overcome the challenge of melanoma drug resistance. In this paper, the group took aim at melanomas ...

which has made it a priority of melanoma researchers. Previous research has indicated that MAPK inhibitors could be a potential therapy for NRAS MUT melanoma. However, on their own, MAPK ...